Daré Bioscience Reports First Quarter 2022 Financial Results and Provides a Company Update
May 12, 2022 06:00 ET
|
Daré Bioscience, Inc.
$39.3 million in cash and cash equivalents at March 31, 2022Announced initiation of DARE-HRT1 Phase 1/2 clinical study in April 2022Organon exclusive global license agreement for...
Daré Bioscience Announces NIH Grant Award
May 11, 2022 08:00 ET
|
Daré Bioscience, Inc.
Supports research to define end-user preferences among U.S. women to informthe design of long-acting injectable hormonal contraception Daré is developing novel injectable formulations of etonogestrel...
Daré Bioscience to Host First Quarter 2022 Financial Results and Company Update Conference Call and Webcast on May 12, 2022
May 05, 2022 08:00 ET
|
Daré Bioscience, Inc.
SAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30...
Daré Bioscience to Participate in Upcoming Conference
April 14, 2022 08:00 ET
|
Daré Bioscience, Inc.
SAN DIEGO, April 14, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and...
Daré Bioscience Initiates Phase 1/2 Clinical Study of DARE-HRT1
April 12, 2022 08:00 ET
|
Daré Bioscience, Inc.
Prior Phase 1 Study Results Support Potential as the First Monthly Therapy for both the Vasomotor and the Vaginal Symptoms of Menopause Current Phase 1/2 Study will Collect Symptom Relief and...
Daré Bioscience Reports Full-Year 2021 Financial Results and Provides a Company Update
March 31, 2022 08:00 ET
|
Daré Bioscience, Inc.
Entered into an exclusive global license agreement with Organon to commercialize XACIATO™ (clindamycin phosphate vaginal gel, 2%) that includes a $10 million upfront cash payment once effective U.S....
Daré Bioscience to Host Full-year 2021 Financial Results and Company Update Conference Call and Webcast on March 31, 2022
March 24, 2022 08:00 ET
|
Daré Bioscience, Inc.
SAN DIEGO, March 24, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast...
Daré Bioscience to Present at the Maxim 2022 Virtual Growth Conference
March 22, 2022 08:00 ET
|
Daré Bioscience, Inc.
SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and CEO, will...
Daré Bioscience to Participate in Upcoming Conferences
March 02, 2022 08:00 ET
|
Daré Bioscience, Inc.
SAN DIEGO, March 02, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that members of its management team will participate in the...
Daré Bioscience to Participate in Upcoming Conferences
February 07, 2022 08:00 ET
|
Daré Bioscience, Inc.
SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief...